Table 2. Effect of the SST Analogue MK678 Peptide and Its Derivatives on EFS-Evoked Total CGRP Release (Percentage Release in the Stimulated and Poststimulated Fractions Together as Compared to the Respective Basal, Nonstimulated, Spontaneous Outflow)a.
| treatment (500 nM) | % CGRP release (comparison to prestimulated fraction) |
|---|---|
| control (Krebs) | 405 ± 58 |
| MK678 | 294 ± 33 |
| 1 | 360 ± 40 |
| 2 | 355 ± 45 |
| 3 | 182 ± 54* |
| 4 | 153 ± 30* |
| 5 | 343 ± 17 |
| 6 | 268 ± 16 |
| 7 | 100 ± 40** |
a
Values are means ± SEM of n = 5 experiments per group. *P < 0.05, and **P < 0.01, vs respective fraction of the control experiment determined with the nonparametric Mann−Whitney U test.